ArticleHuman molecular genetics2026
Cell-type-specific dysregulated gene expression in the frontal cortex of an Angelman syndrome pig model.
Article in Human molecular genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neuronal UBE3A loss engages a TNF-driven neuron-to-microglia axis that promotes synapse remodeling.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Angelman syndrome is a neurodevelopmental disorder caused by the loss of the maternal allele of the ubiquitin-protein ligase E3A (UBE3A) gene. UBE3A is imprinted with maternal-allelic expression in neurons of the central nervous system (CNS) and biallelic expression in other cell types. Consequently, in Angelman syndrome, UBE3A is substantially reduced in CNS neurons and reduced by half in other cells. It is unclear how cell-type-specific gene expression in the brain is dysregulated in Angelman syndrome, as previous studies have lacked cell type resolution. Using single nuclei RNA-sequencing, we show that gene expression is dysregulated in neuronal subtypes in the frontal cortex of neonatal pigs with a UBE3A maternal deletion. A total of 3812 unique genes were dysregulated across ten cell type clusters, with most of the dysregulated genes (3154 genes) in excitatory neurons. Pathway analysis revealed alterations in oxidative phosphorylation, proteasome function, and synaptic function. Additionally, somatostatin (SST)-a secreted neuropeptide involved in GABAergic inhibition and synaptic plasticity- was reduced in inhibitory neurons in the cortex and hypothalamus, which correlated with lower circulating SST protein in neonates but not adolescent pigs. Overall, these findings provide greater clarity on the cell-type-specific dysregulation of gene expression and cellular pathways caused by the loss of UBE3A in CNS neurons, expanding our understanding of the molecular pathology in Angelman syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.